Chronic Pain Pipeline

DelveInsight’s, “Chronic Pain Pipeline Insight, 2026” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Chronic pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Pain Understanding

Chronic Pain Overview

Chronic pain is a complex and multifactorial condition characterized by persistent or recurrent pain lasting longer than three months, often extending beyond the normal period of tissue healing. It may arise from injury, disease, nerve dysfunction, or unknown causes and can significantly impair physical function, emotional well-being, and quality of life. As a major global health burden, chronic pain is frequently associated with comorbid conditions such as anxiety, depression, and sleep disturbances, highlighting the need for comprehensive and individualized management strategies. 

Chronic pain can result from a wide range of underlying conditions, including musculoskeletal disorders, nerve injuries, inflammatory diseases, cancer, infections, and trauma. In some individuals, pain persists even after the initial injury or illness has resolved due to changes in pain-processing pathways within the peripheral and central nervous systems. Psychological, genetic, and environmental factors may also contribute to the development and persistence of chronic pain.

The pathophysiology of chronic pain involves persistent activation and sensitization of the peripheral and central nervous systems, leading to an exaggerated pain response that can continue even after tissue healing has occurred. Ongoing inflammation, nerve injury, and neuroplastic changes in the spinal cord and brain contribute to altered pain signaling, resulting in heightened pain perception, reduced pain inhibition, and the maintenance of chronic pain states.

Diagnosis of chronic pain is primarily based on a comprehensive clinical assessment, including a detailed history of pain duration, intensity, characteristics, and its impact on daily functioning. Physical examination, along with appropriate laboratory tests, imaging studies, or neurological evaluations, may be used to identify underlying causes and rule out other conditions. Assessment of psychological and social factors is also important, as these can significantly influence pain perception and treatment outcomes.

Treatment of chronic pain typically involves a multimodal approach aimed at reducing pain, improving function, and enhancing quality of life. Management may include pharmacological therapies such as analgesics and adjuvant medications, combined with physical therapy, psychological interventions, lifestyle modifications, and, when appropriate, interventional procedures. Individualized treatment plans that address both the physical and psychosocial aspects of pain are essential for achieving optimal outcomes.

"Chronic Pain Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Pain pipeline landscape is provided which includes the disease overview and Chronic Pain treatment guidelines. The assessment part of the report embraces, in depth Chronic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Chronic Pain Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Pain. 

Chronic Pain Emerging Drugs Analysis

This segment of the Chronic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Pain Emerging Drugs

BRTX-100: BioRestorative Therapies, Inc.

BRTX-100 is an autologous cell therapy developed by BioRestorative Therapies for the treatment of chronic pain associated with lumbar disc disease. The therapy is formulated from a patient's own cultured mesenchymal stem cells obtained from bone marrow and is designed for direct injection into damaged intervertebral discs. By delivering these stem cells to the affected disc environment, BRTX-100 aims to provide a non-surgical regenerative approach for painful lumbosacral disc disorders and chronic low back pain that has not responded to conservative treatments. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Pain.

VX-993: Vertex Pharmaceuticals Incorporated

VX-993 is an investigational, orally administered selective NaV1.8 pain signal inhibitor developed by Vertex Pharmaceuticals for the treatment of pain conditions. The drug works by selectively inhibiting the NaV1.8 voltage-gated sodium channel, a key mediator of pain signal transmission in peripheral sensory neurons. By blocking NaV1.8 activity, VX-993 is designed to reduce the generation and propagation of pain signals without targeting opioid pathways, supporting a non-opioid approach to pain management. . Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Pain.

ST-503: Sangamo Therapeutics

ST-503 is an investigational epigenetic regulator developed by Sangamo Therapeutics for the treatment of chronic neuropathic pain. The therapy utilizes an adeno-associated virus (AAV) vector carrying an engineered zinc finger repressor that specifically targets the SCN9A gene, which encodes the Nav1.7 sodium channel, a key mediator of pain signaling. By selectively reducing Nav1.7 expression in sensory neurons, ST-503 is designed to diminish pain transmission and provide durable relief from chronic, intractable pain. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Chronic Pain.

SBS-147: Sparian Biosciences

SBS-147 is an oral, first-in-class arylepoxamide receptor (AEAr) agonist from Sparian Biosciences being developed for chronic pain. It works by activating the newly identified AEAr receptor involved in pain pathways, producing potent analgesic effects in preclinical models while avoiding key opioid-associated liabilities such as respiratory depression, physical dependence, and reward behavior. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Chronic Pain.

Further product details are provided in the report……..

Chronic Pain Drug Therapeutic Assessment

This segment of the report provides insights about the different Chronic Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Chronic Pain Players in Chronic Pain

There are approx. 15+ key companies which are developing the therapies Chronic Pain. The companies which have their Chronic Pain drug candidates in the most advanced stage, i.e. Phase II include, BioRestorative Therapies, Inc., and others.

Chronic Pain Clinical Trial Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Chronic Pain Route of Administration

Chronic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Chronic Pain Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Chronic Pain Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Pain Clinical Trial Activities 

The Chronic Pain Pipeline report provides insights into different Chronic Pain Clinical Trial within phase II, I, preclinical and discovery stage. It also analyses Chronic Pain therapeutic drugs key players involved in developing key drugs. 

Chronic Pain Pipeline Development Activities

The Chronic Pain Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Pain drugs.

Chronic Pain Report Insights

• Chronic Pain Pipeline Analysis
• Chronic Pain Therapeutic Assessment
• Chronic Pain Unmet Needs
• Impact of Chronic Pain Drugs

Chronic Pain Report Assessment

• Chronic Pain Pipeline Product Profiles
• Chronic Pain Therapeutic Assessment
• Chronic Pain Pipeline Assessment
• Chronic Pain Inactive drugs assessment
• Chronic Pain Market Unmet Needs

Key Questions Answered in the Chronic Pain Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Chronic Pain drugs?
• How many Chronic Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Pain?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Pain therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Chronic Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Chronic Pain Key Players

• BioRestorative Therapies, Inc.
• Sangamo Therapeutics
• Vertex Pharmaceuticals Incorporated
• Sparian Biosciences
• Centrexion Therapeutics
• Eli Lilly and Company
• Conana Bio
• Interventional Analgesix Inc.
• Eli Lilly and Company
• Vertanical GmbH
• Creative Medical Technology Holdings Inc
• Eli Lilly and Company
• iN Therapeutics Co., Ltd.

Chronic Pain Key Products

• BRTX-100
• ST-503
• VX-993
• SBS-147
• CNTX-3001
• LY3016859
• C-1101
• ITX24-01
• Retatrutide
• VER-01
• CELZ-201
• LY4065967
• iN1011-N17